Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

Table 1 Overview of evaluable treatments per patient

Patient ID	Evaluable treatment 1	Response 1	Evaluable treatment 2	Response 2	Evaluable treatment 3	Response 3	Mutational status	PDO origin	Stage at presentation	Sidedness
04	5-FU	SD	5-FU & irinotecan	SD	5-FU & oxaliplatin	PR	RAS mutant	Metastatic	IV	Left
06	5-FU	SD					RAS mutant	Metastatic	IV	Left
07	5-FU	SD					RAS mutant	Metastatic	IV	Left
11	5-FU	PD					Wildtype	Metastatic	IV	Right
16	5-FU	SD	Panitumumab	PD			BRAF mutant	Primary	IV	Right
18	5-FU	PD					Wildtype	Metastatic	III	Rectum
01	Irinotecan	SD					RAS mutant	Metastatic	II	Rectum
02	5-FU & irinotecan	SD					RAS mutant	Metastatic	III	Right
23	5-FU & irinotecan	SD	Panitumumab	SD			BRAF mutant	Metastatic	III	Left
20	5-FU & irinotecan	PD
20	5-FU & oxaliplatin	PD					RAS mutant	Primary	IV	Left
03	5-FU & oxaliplatin	PD					RAS mutant	Primary	IV	Right
05	5-FU & oxaliplatin	PR					RAS mutant	Primary	IV	Right
08	5-FU & oxaliplatin	PR			Panitumumab	SD	Wildtype	Metastatic	IV	Rectum
09	5-FU & oxaliplatin	SD					BRAF mutant	Metastatic	IV	Left
10	5-FU & oxaliplatin	PR	Panitumumab	SD			Wildtype	Metastatic	IV	Left
12	5-FU & oxaliplatin	PR	5-FU & irinotecan	SD	Panitumumab	SD	Wildtype	Metastatic	IV	Left
13	5-FU & oxaliplatin	SD	Irinotecan	SD			RAS mutant	Metastatic	IV	Left
14	5-FU & oxaliplatin	PR	5-FU & irinotecan	PR			Wildtype	Metastatic	III	Rectum
15	5-FU & oxaliplatin	PR	5-FU & irinotecan	SD	Panitumumab	SD	Wildtype	Metastatic	III	Rectum
17	5-FU & oxaliplatin	PR	5-FU & irinotecan	SD			RAS mutant	Metastatic	IV	Right
19	5-FU & oxaliplatin	PD					Wildtype	Metastatic	III	Left
21	5-FU & oxaliplatin	PD					Wildtype	Metastatic	II	Right
22	Panitumumab	PR					Wildtype	Metastatic	IV	Left

Table describing the evaluable treatments, ranked per primary evaluable treatment. The first, second and third lines after organoid establishment are shown for each patient, along with the patient’s best RECIST response during treatment. The RAS/BRAF mutational status of the original tumour, PDO origin, tumour stage at presentation and primary tumour location (sidedness) are presented. All patients had a proficient mismatch repair (pMMR) tumour. Patient 20 was resistant to FOLFOXIRI triplet chemotherapy and is, therefore, evaluable for 5-FU & oxaliplatin and 5-FU & irinotecan. Clinically capecitabine (prodrug 5-FU) is used often, while in in vitro screens 5-FU is evaluated
5-FU 5 Fluorouracil, CAP Capecitabine, ID Identification, PD Progressive disease, PDO Patient-derived organoid, PR Partial response, SD Stable disease

ISSN: 1756-9966